ADQ to Acquire Amoun Pharmaceutical from Bausch Health for ~$740M

 ADQ to Acquire Amoun Pharmaceutical from Bausch Health for ~$740M

ADQ to Acquire Amoun Pharmaceutical from Bausch Health for ~$740M

Shots:

  • ADQ to acquire all the outstanding shares of Amoun Pharmaceutical from Bausch Health for ~$740M. The transaction is expected to close in H1’21
  • The divestiture is part of its planned separation of Bausch & Lomb eye-care division
  • The sale of Amoun marks important progress to reduce overall Bausch Health debt and plans to prepare for the spinoff of Bausch + Lomb

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Financial Post

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post